首页> 外文期刊>Kidney Research and Clinical Practice >Therapeutic effects of epigallocatechin gallate on streptozotocin-induced diabetic nephropathy in mice.
【24h】

Therapeutic effects of epigallocatechin gallate on streptozotocin-induced diabetic nephropathy in mice.

机译:表没食子儿茶素没食子酸酯对链脲佐菌素诱发的小鼠糖尿病肾病的治疗作用。

获取原文
       

摘要

Diabetic nephropathy is one of the most serious complications in diabetes mellitus and has been the most common cause of end-stage renal disease. Green tea extracts have antioxidant properties, and (-)-epigallocatechin 3-O-gallate (EGCG) is known to be the most abundant in green tea. Osteopontin (OPN) is a large phosphoglycoprotein adhesion molecule, and has emerged as a potentially key pathophysiologic contributor in diabetic nephropathy. We examined whether EGCG could amelliorate the development of diabetic nephropathy and its role of OPN. The mice (n=28) were divided into 3 groups. Control group (n=7) was intraperitoneal (IP) injected 0.9% saline, Streptozotocin (STZ) group (n=7) was IP injected STZ 200mg/Kg and induced diabetic nephropathy. After a 8weeks, EGCG groups (n=7/each group) were received EGCG 50mg/kg and 100mg/kg body weight by subcutaneous injection. Serum glucose, blood urea nitrogen, serum creatinine, urine volume and urine protein amounts were measured. Western blot assay of OPN was compared for the different groups. Histopathologic examination and immunohistochemical staining of mice kidney were performed. Compared with control group, STZ-group showed an increase in blood glucose, blood urea nitrogen, creatinine levels and urine protein amounts, and a decrease in body weight. All the above parameters were significantly reversed with EGCG treatment. After STZ injection, there were an diabetic glomerulosclerosis with increased renal OPN accumulation and its protein expression in the kidney cortex. EGCG-treated mice kidney showed a reduced expression of above parameters and an reserved pathologic findings. These results suggest that EGCG ameliorates STZ-induced diabetic nephropathy by OPN suppression. The potential use of EGCG in the treatment of diabetic nephropathy should be further explored.
机译:糖尿病肾病是糖尿病中最严重的并发症之一,并且已经是终末期肾脏疾病的最常见原因。绿茶提取物具有抗氧化性能,(-)-表没食子儿茶精3-O-没食子酸酯(EGCG)已知是绿茶中含量最高的。骨桥蛋白(OPN)是一个大的磷酸糖蛋白粘附分子,已成为糖尿病性肾病的潜在关键病理生理因素。我们检查了EGCG是否可以改善糖尿病性肾病的发展及其在OPN中的作用。将小鼠(n = 28)分为3组。对照组(n = 7)腹膜内(IP)注射0.9%生理盐水,链脲佐菌素(STZ)组(n = 7)腹膜内注射STZ 200mg / Kg,诱发糖尿病性肾病。 8周后,通过皮下注射给予EGCG组(n = 7 /每组)EGCG 50mg / kg和100mg / kg体重。测量血清葡萄糖,血尿素氮,血清肌酐,尿量和尿蛋白量。比较了不同组的OPN的蛋白质印迹法。进行了小鼠肾脏的组织病理学检查和免疫组织化学染色。与对照组相比,STZ组的血糖,血尿素氮,肌酐水平和尿蛋白含量增加,体重下降。 EGCG处理可明显逆转上述所有参数。注射STZ后,出现糖尿病性肾小球硬化,肾脏OPN积累增加,其蛋白在肾皮质中表达。 EGCG处理的小鼠肾脏显示上述参数表达降低,并保留了病理学发现。这些结果表明,EGCG通过OPN抑制改善了STZ诱导的糖尿病性肾病。 EGCG在糖尿病肾病治疗中的潜在用途应进一步探索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号